PAVLODAR – One Kazakhstan-based pharmaceutical company has partnered with 120 companies around the world in manufacturing medicine.
President of the Pavlodar-based pharmaceutical holding Romat, Turarbek Rakish, academician and doctor of sciences, as well as honored engineer of Kazakhstan, chevalier of the Order of Lomonossov and a holder of other awards, has his own motto – he who walks deals with the road. By exerting great energy and possessing great talent, Rakish has turned a small pharmacy into a major corporation and one of the leading pharmaceutical companies in Kazakhstan with worldwide recognition. Today, Romat operates three modern plants for the production of medicines, biological products, medical devices and polymer instruments and a national network of distributors and retail pharmacies. In the long term, they plan to create new capacities.
According to recommendations from the World Health Organisation, in order to ensure strategic security for the state, the share of domestically manufactured medicines in relation to imports should not be less than 20 percent. That’s why one of the top development priorities of the country is to increase the share of medicines produced domestically in Kazakhstan to 40-50 percent by 2014. The pharmaceutical sector is included in the State Programme of Accelerated Industrial and Innovative Development (SPAIID).
But today, the production of drugs, especially new and more effective pharmaceuticals, is not only an effort on the part of individual pharmaceutical companies and national associations, but also that of interstate partnerships. This is why Romat has been successfully developing international relations with their colleagues and today has partnerships with more than 120 companies worldwide, namely manufacturers of drugs and medical equipment. Its portfolio always includes products from well-known foreign manufacturers of pharmaceuticals, such as Eli Lilly (Switzerland), GSK (Britain), Nestle (Switzerland), Nycomed (Austria), NovoNordisk (Denmark), Pfizer (USA), Schering AG (Germany.)
In partnership with Russian scientists, the company has created new and unique drugs at a chemical-pharmaceutical research centre headed by Kunnaz Murzagulov, the inventor of a number of drugs, doctor of chemical sciences, merited professional of healthcare of the Republic of Kazakhstan and member of the American Chemical Society. One of the significant achievements of the centre is the creation of a radically new anti-tuberculosis agent which was patented in the CIS. Thanks to this drug, doctors in Kazakhstan have already achieved significant results in the treatment of tuberculosis. European pharmaceutical companies have used this medication.
Together with its Russian partners, the holding also launched a project to cure various cancers through the transfer of active pharmaceutical ingredients via nanocapsules and microcapsules.
The original anesthetic and anti-arrhythmic drug Rihlokain is a joint creation of Kazakhstan and Russian scientists. In oncology, this is recommended for effective treatment of ovarian and breast cancer. It was proved that Rihlokain surpasses all competing drugs in therapeutic effects, causing almost instantaneous anesthesia. It has dermatic-protective properties as well. Scientists believe it to be a breakthrough of great significance. Moreover, this drug is able to break the process of viral reproduction, which makes it promising in the development of new HIV treatments.
“The new drug was made possible thanks to the joint efforts of Russia and Kazakhstan-based chemists, pharmacists, engineers, industrialists and environmentalists,” said director of the Institute of Biomedical Problems of the Russian Academy of Sciences, Academician Anatoly Panov. “Our collaborative work greatly accelerated the creation of the original pharmaceutics.”
This opinion is shared by Rakish. ”The production of Rihlokain will allow us to manufacture an additional 35 kinds of products, at the minimum,” he added.
Today, Romat continues its partnership with Russian scientists in creating medicines to serve the coming generations.
